Literature DB >> 8036042

Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics.

A M Knott1, C E Long, C B Hall.   

Abstract

Parainfluenza types 1, 2 and 3 were studied in a pediatric outpatient population from 1976 to 1992 to compare seasonal patterns over time and to define better the spectrum of illness in all ages of children caused by these viruses. Parainfluenza type 1 occurred in the fall of odd numbered years; parainfluenza type 2 was less predictable; and parainfluenza type 3 appeared yearly with peak activity in spring or summer. The parainfluenza viruses were the major cause of croup and also accounted for one-half of the cases of laryngitis and over one-third of all lower respiratory tract illness in children from whom a virus was isolated. The major clinical manifestations of infection with parainfluenza types 1 and 2 were croup, upper respiratory infections and pharyngitis; for parainfluenza type 3 upper respiratory tract infection was predominant in all age groups. The parainfluenza viruses cause appreciable respiratory morbidity each year among infants and young children. They are the major cause of croup but also produce a spectrum of diseases ranging from mild upper respiratory tract infection to bronchiolitis and pneumonia. Most studies have focused on the morbidity of parainfluenza viruses in infants and young children who are hospitalized. Less appreciated is the impact of parainfluenza viral infections in outpatients and in older children. The parainfluenza viruses have a striking epidemiologic pattern which has evolved over the past 30 years. In the early 1960s parainfluenza types 1, 2 and 3 were all reported to be endemic.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8036042     DOI: 10.1097/00006454-199404000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  24 in total

1.  Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time.

Authors:  Celalettin Ustun; Jiří Slabý; Ryan M Shanley; Jan Vydra; Angela R Smith; John E Wagner; Daniel J Weisdorf; Jo-Anne H Young
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-21       Impact factor: 5.742

2.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Isolation and characterization of a naturally occurring parainfluenza 3 virus variant.

Authors:  E M Swierkosz; D D Erdman; T Bonnot; C Schneiderheinze; J L Waner
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

4.  Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.

Authors:  H Laurichesse; D Dedman; J M Watson; M C Zambon
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

5.  Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.

Authors:  Irina V Alymova; Allen Portner; Vasiliy P Mishin; Jonathan A McCullers; Pamela Freiden; Garry L Taylor
Journal:  Glycobiology       Date:  2011-08-16       Impact factor: 4.313

6.  Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Authors:  Irina V Alymova; Garry Taylor; Toru Takimoto; Tsu-Hsing Lin; Pooran Chand; Y Sudhakara Babu; Chenghong Li; Xiaoping Xiong; Allen Portner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs.

Authors:  Branka Grubor; Jack M Gallup; David K Meyerholz; Erika C Crouch; Richard B Evans; Kim A Brogden; Howard D Lehmkuhl; Mark R Ackermann
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

8.  Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Authors:  Irina V Alymova; Garry Taylor; Vasiliy P Mishin; Makiko Watanabe; K Gopal Murti; Kelli Boyd; Pooran Chand; Y Sudhakara Babu; Allen Portner
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Authors:  Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt
Journal:  Vaccine       Date:  2007-07-03       Impact factor: 3.641

10.  Human parainfluenza virus-associated respiratory tract infection among children and genetic analysis of HPIV-3 strains in Beijing, China.

Authors:  Naiying Mao; Yixin Ji; Zhengde Xie; Huanhuan Wang; Huiling Wang; Junjing An; Xinxin Zhang; Yan Zhang; Zhen Zhu; Aili Cui; Songtao Xu; Kunling Shen; Chunyan Liu; Weizhong Yang; Wenbo Xu
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.